跳转至内容
Merck

SML1522

Sigma-Aldrich

Doxofylline

≥98% (HPLC)

别名:

7-(1,3-Dioxolan-2-ylmethyl)-1,3-dimethylpurine-2,6-dione, 7-(1,3-Dioxolan-2-ylmethyl)theophylline

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C11H14N4O4
CAS号:
分子量:
266.25
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77

品質等級

化驗

≥98% (HPLC)

形狀

powder

顏色

white to beige

溶解度

H2O: 2 mg/mL, clear (warmed)

儲存溫度

2-8°C

SMILES 字串

CN1C2=C(N(CC3OCCO3)C=N2)C(N(C)C1=O)=O

InChI

1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3

InChI 密鑰

HWXIGFIVGWUZAO-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

Doxofylline is a novel xanthine derivative comprising of dioxolone group.

應用

Doxofylline has been used as a phosphodiesterase (PDE) inhibitor to study its protective effects on lipopolysaccharides (LPS)-induced inflammatory response in human pulmonary bronchial epithelial cells. It has also been used to study its interaction with bovine serum albumin (BSA).

生化/生理作用

Doxofylline (also known as doxophylline) has antitussive and bronchodilator effects. Doxofylline is used clinically in the treatment of asthma. Doxofylline has similar efficacy to theophylline, but unlike theophylline or other xanthines has little affinity for adenosine receptors and does not produce stimulant effects and has significantly fewer side effects.
Doxofylline acts and as a non-selective phosphodiesterase (PDE) inhibitor and exhibits anti-inflammatory activity. It has the potential to treat chronic obstructive pulmonary disease (COPD).

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sami Manzoor Margay et al.
Journal of clinical and diagnostic research : JCDR, 9(4), FC05-FC08 (2015-05-30)
Asthma is a non communicable chronic disease prevalent all over the world. Two commonly used methylxanthines, theophylline and doxofylline were compared in the study in stable asthmatic patients at recommended doses by various spirometric lung function tests with forced expiratory
Muhasaparur Ganesan Rajanandh et al.
Clinical therapeutics, 37(2), 418-426 (2015-01-13)
Data comparing various second-line treatments for asthma with subjective and objective assessment are lacking. This study aimed to compare the efficacy and safety of montelukast, doxofylline, and tiotropium with a low-dose budesonide in patients with mild to moderate persistent asthma.
Dushyant Lal et al.
Journal of basic and clinical physiology and pharmacology, 26(5), 443-451 (2015-04-22)
Bronchial asthma and chronic obstructive pulmonary disease (COPD) are the major obstructive disorders that may contribute to the severity in individual patients. The present study was designed to compare the efficacy and safety of theophylline and doxofylline in patients with
R Cirillo et al.
Archives internationales de pharmacodynamie et de therapie, 295, 221-237 (1988-09-01)
In the present study the interaction of doxofylline, a new antiasthmatic drug, with A1- and A2-adenosine receptors of the guinea-pig brain and rat striatum was investigated in comparison with known methylxanthine derivatives. Inhibition studies of N6-cyclohexyl-3H-adenosine (3H-CHA), 1,3-diethyl-8-3H-phenylxanthine (3H-DPX) binding
Sokratis Katsikas et al.
Studies in health technology and informatics, 134, 113-125 (2008-04-01)
The health care sector is quickly exploiting Information and Communication Technologies towards the provision of e-health services. According to recent surveys, one of the most severe restraining factors for the proliferation of e-health is the (lack of) security measures required

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门